• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

6.310 +0.340 (+5.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entrada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Recap: Entrada Therapeutics Q4 Earnings ↗
March 13, 2024
 
Via Benzinga
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know ↗
November 27, 2023
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
November 23, 2023
 
Via Benzinga
News headline image
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? ↗
November 22, 2023
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
November 22, 2023
 
Via Benzinga
News headline image
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
August 01, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
June 26, 2023
 
Via Benzinga
News headline image
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
News headline image
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 04, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗
April 03, 2023
 
Via Benzinga
News headline image
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 29, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
March 09, 2023
 
Via Benzinga
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
February 16, 2023
 
Via Benzinga
News headline image
Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
February 15, 2023
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
February 15, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap